SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.87-2.2%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: XenaLives who wrote (3476)4/20/2001 11:22:08 AM
From: Biomaven  Read Replies (3) of 52153
 
Paula,

I haven't been following RGEN of late, but the GNLB moves were more than just bad journalism. The FDA briefing posted ahead of the Advisory Committee meeting was very negative, and not surprisingly the stock plunged. The AC meeting itself was more positive than could have reasonably been predicted based on the FDA briefing, and hence the recovery. Thus to my mind the GNLB moves have all been rational.

I'd be very cautious holding GNLB for long. With the FDA in its present mood I doubt they will jump to approve.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News